Certification Underscores Sightview Software’s High Standards in Healthcare Data Security
RALEIGH, NC / ACCESSWIRE / September 19, 2024 / Sightview Software, a leading software provider for eye care practices nationwide, today announced that its iMedicWare™ platform has achieved Level 2 Certification from the Texas Risk and Authorization Management Program (TX-RAMP). This certification, granted by the Texas Department of Information Resources (DIR), represents the highest level of security compliance for cloud products and services that handle sensitive data for Texas state agencies.
The TX-RAMP Level 2 Certification follows a rigorous year-long assessment process, evaluating iMedicWare’s infrastructure, security features, and Sightview’s overall security practices. This achievement underscores Sightview’s commitment to maintaining the highest standards of data protection and privacy in the healthcare technology sector.
“Achieving TX-RAMP Level 2 Certification is a testament to our unwavering commitment to data security and our customers’ trust,” said Sophie Turrell, CEO of Sightview. “In an era where protecting sensitive healthcare information is paramount, this certification demonstrates that iMedicWare not only meets but exceeds the stringent security standards required for handling critical patient data.”
The certification process involved a comprehensive evaluation of Sightview’s security policies, data flow diagrams, risk management framework, and the robust infrastructure provided by Amazon Web Services (AWS). The TX-RAMP Level 2 Certification also requires ongoing compliance through continuous monitoring, ensuring that iMedicWare maintains its high security standards over time.
This achievement allows iMedicWare to be deployed within Texas state agencies, opening new opportunities for Sightview in the public sector while reinforcing its position as a leader in secure healthcare technology solutions.
Contact Information
Nicholas Peddle
VP of Marketing
nicholas.peddle@sightview.com
SOURCE: Sightview Software
View the original press release on newswire.com.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…
